Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs FDC - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA FDC ASTRAZENECA PHARMA/
FDC
 
P/E (TTM) x 149.3 22.8 653.5% View Chart
P/BV x 41.9 4.4 948.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   FDC
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
FDC
Mar-18
ASTRAZENECA PHARMA/
FDC
5-Yr Chart
Click to enlarge
High Rs1,278319 400.6%   
Low Rs883164 538.2%   
Sales per share (Unadj.) Rs228.461.6 370.5%  
Earnings per share (Unadj.) Rs10.49.9 104.2%  
Cash flow per share (Unadj.) Rs16.312.0 135.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.873.2 135.0%  
Shares outstanding (eoy) m25.00174.40 14.3%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.73.9 120.7%   
Avg P/E ratio x104.224.3 429.4%  
P/CF ratio (eoy) x66.420.2 329.1%  
Price / Book Value ratio x10.93.3 331.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,00842,118 64.1%   
No. of employees `0001.45.5 24.5%   
Total wages/salary Rs m1,5352,167 70.9%   
Avg. sales/employee Rs Th4,210.91,943.7 216.6%   
Avg. wages/employee Rs Th1,132.2391.7 289.0%   
Avg. net profit/employee Rs Th191.1313.7 60.9%   
INCOME DATA
Net Sales Rs m5,71010,751 53.1%  
Other income Rs m123510 24.0%   
Total revenues Rs m5,83311,260 51.8%   
Gross profit Rs m4632,267 20.4%  
Depreciation Rs m147351 41.9%   
Interest Rs m014 0.0%   
Profit before tax Rs m4382,411 18.2%   
Minority Interest Rs m0-5 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179671 26.7%   
Profit after tax Rs m2591,735 14.9%  
Gross profit margin %8.121.1 38.4%  
Effective tax rate %40.827.8 146.7%   
Net profit margin %4.516.1 28.1%  
BALANCE SHEET DATA
Current assets Rs m3,2097,213 44.5%   
Current liabilities Rs m2,0702,104 98.4%   
Net working cap to sales %20.047.5 42.0%  
Current ratio x1.63.4 45.2%  
Inventory Days Days7254 132.7%  
Debtors Days Days3528 126.0%  
Net fixed assets Rs m7906,865 11.5%   
Share capital Rs m50175 28.5%   
"Free" reserves Rs m2,41912,586 19.2%   
Net worth Rs m2,46912,761 19.4%   
Long term debt Rs m06 0.0%   
Total assets Rs m4,60515,041 30.6%  
Interest coverage xNM173.2-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 173.5%   
Return on assets %5.611.6 48.4%  
Return on equity %10.513.6 77.2%  
Return on capital %17.719.0 93.6%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3001,889 15.9%   
Fx outflow Rs m2,0150-   
Net fx Rs m-1,7151,889 -90.8%   
CASH FLOW
From Operations Rs m881,498 5.9%  
From Investments Rs m-94201 -46.5%  
From Financial Activity Rs mNA-1,694 0.0%  
Net Cashflow Rs m-610 -55.3%  

Share Holding

Indian Promoters % 0.0 68.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.7 6.4%  
FIIs % 15.7 7.5 209.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 19.0 47.9%  
Shareholders   12,856 23,730 54.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  STERLING BIOTECH  WOCKHARDT  SUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Lower; IndusInd Bank & Tata Steel Top Losers(09:30 am)

Asian stock markets are trading on a mixed note today as disappointing news on US consumer spending dampened sentiment ahead of a closely-watched reading on the health of the Chinese economy.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (3QFY20); Net Profit Up 67.7% (Quarterly Result Update)

Feb 10, 2020 | Updated on Feb 10, 2020

For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (2QFY20); Net Profit Up 45.4% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, FDC LTD. has posted a net profit of Rs 627 m (up 45.4% YoY). Sales on the other hand came in at Rs 3 bn (up 28.8% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 18, 2021 09:44 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS